JP2021527041A5 - - Google Patents
Info
- Publication number
- JP2021527041A5 JP2021527041A5 JP2020567772A JP2020567772A JP2021527041A5 JP 2021527041 A5 JP2021527041 A5 JP 2021527041A5 JP 2020567772 A JP2020567772 A JP 2020567772A JP 2020567772 A JP2020567772 A JP 2020567772A JP 2021527041 A5 JP2021527041 A5 JP 2021527041A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/090004 | 2018-06-05 | ||
| CN2018090004 | 2018-06-05 | ||
| EP18193916.6 | 2018-09-12 | ||
| EP18193916 | 2018-09-12 | ||
| CN2019086019 | 2019-05-08 | ||
| CNPCT/CN2019/086019 | 2019-05-08 | ||
| PCT/EP2019/064323 WO2019233941A1 (en) | 2018-06-05 | 2019-06-03 | Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021527041A JP2021527041A (ja) | 2021-10-11 |
| JP2021527041A5 true JP2021527041A5 (https=) | 2023-07-11 |
| JPWO2019233941A5 JPWO2019233941A5 (https=) | 2023-07-11 |
| JP7374130B2 JP7374130B2 (ja) | 2023-11-06 |
Family
ID=66793968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567772A Active JP7374130B2 (ja) | 2018-06-05 | 2019-06-03 | 自己免疫疾患治療用の新規なテトラヒドロ－１Ｈ－ピラジノ［２，１－ａ］イソインドリルキノリン化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12157746B2 (https=) |
| EP (1) | EP3802539B1 (https=) |
| JP (1) | JP7374130B2 (https=) |
| KR (1) | KR20210018818A (https=) |
| CN (1) | CN112204028B (https=) |
| AU (1) | AU2019280728A1 (https=) |
| BR (1) | BR112020024782A2 (https=) |
| CA (1) | CA3098291A1 (https=) |
| CL (1) | CL2020003065A1 (https=) |
| CO (1) | CO2020014677A2 (https=) |
| CR (1) | CR20200584A (https=) |
| IL (1) | IL279144A (https=) |
| MA (1) | MA52747A (https=) |
| MX (1) | MX2020012827A (https=) |
| PE (1) | PE20210131A1 (https=) |
| PH (1) | PH12020552092A1 (https=) |
| SG (1) | SG11202011137SA (https=) |
| TW (1) | TW202016111A (https=) |
| WO (1) | WO2019233941A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021084022A1 (en) | 2019-10-31 | 2021-05-06 | F. Hoffmann-La Roche Ag | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| CN114728959B (zh) * | 2019-11-12 | 2024-11-12 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡嗪并[1,2-b]异喹啉化合物 |
| US12503471B2 (en) | 2019-11-19 | 2025-12-23 | Hoffmann-La Roche Inc. | Triazatricycle compounds for the treatment of autoimmune disease |
| CN114728976B (zh) * | 2019-11-19 | 2024-08-16 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物 |
| WO2021110614A1 (en) | 2019-12-03 | 2021-06-10 | F. Hoffmann-La Roche Ag | HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE |
| US20240317735A1 (en) | 2020-07-14 | 2024-09-26 | Hoffmann-La Roche Inc. | Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease |
| WO2022022489A1 (zh) * | 2020-07-27 | 2022-02-03 | 江苏恒瑞医药股份有限公司 | 吲哚稠环类衍生物、其制备方法及其在医药上的应用 |
| CN114057759B (zh) * | 2020-08-07 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
| AU2021385752A1 (en) * | 2020-11-26 | 2023-06-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused tricyclic compound, preparation method therefor and application thereof in medicine |
| WO2023025109A1 (zh) * | 2021-08-23 | 2023-03-02 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
| CN114656363A (zh) * | 2022-03-28 | 2022-06-24 | 南京林业大学 | 一种钯催化芳香酯类化合物的合成方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4273773A (en) | 1979-09-24 | 1981-06-16 | American Home Products Corporation | Antihypertensive tricyclic isoindole derivatives |
| BRPI0418127A (pt) | 2003-12-24 | 2007-04-27 | Biota Scient Management | uso de um composto, seus sais, e derivados farmaceuticamente aceitáveis dos mesmos, método para o tratamento de infecções envolvendo vìrus da sub-famìlia pneumovirinae, formulação farmacêutica, métodos para tratar mamìferos infectados e para prevenir a infecção de mamìferos com vìrus da sub-famìlia pneumovirinae, composto, seus sais, e derivados farmaceuticamente aceitáveis dos mesmos, composto e a forma n-óxido e sal piridìnio do mesmo, e, método de separação de enantiÈmeros de um composto |
| WO2011106276A1 (en) * | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| SG11201509520QA (en) | 2013-05-24 | 2015-12-30 | Janssen Sciences Ireland Uc | Pyridone derivatives for the treatment of viral infections and further diseases |
| JP6223563B2 (ja) | 2013-10-14 | 2017-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的に置換されたキノリン化合物 |
| CN105636945B (zh) | 2013-10-14 | 2017-11-17 | 卫材R&D管理有限公司 | 选择性取代的喹啉化合物 |
| CA3005766A1 (en) | 2015-12-17 | 2017-06-22 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| BR112019001270A2 (pt) | 2016-07-30 | 2019-04-30 | Bristol-Myers Squibb Company | compostos indol substituídos com dimetoxifenila como inibidores de tlr7, tlr8 ou tlr9 |
| JP7125385B2 (ja) | 2016-08-08 | 2022-08-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
| JP7028861B2 (ja) | 2016-09-09 | 2022-03-02 | ブリストル－マイヤーズ スクイブ カンパニー | ピリジル置換のインドール化合物 |
| HRP20220144T1 (hr) | 2016-09-09 | 2022-04-15 | Novartis Ag | Spojevi i pripravci kao inhibitori endosomskih toll-u sličnih receptora |
| EP3655401B1 (en) | 2017-07-18 | 2023-09-06 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
| KR102688509B1 (ko) | 2017-08-04 | 2024-07-24 | 브리스톨-마이어스 스큅 컴퍼니 | [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물 |
| WO2019028302A1 (en) | 2017-08-04 | 2019-02-07 | Bristol-Myers Squibb Company | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR7 / 8/9 INHIBITORS |
| SI3692040T1 (sl) | 2017-10-05 | 2023-05-31 | Glaxosmithkline Intellectual Property Development Limited | Kemijske spojine |
| JP7265554B2 (ja) | 2017-11-14 | 2023-04-26 | ブリストル－マイヤーズ スクイブ カンパニー | 置換インドール化合物 |
| KR102781141B1 (ko) | 2017-12-15 | 2025-03-13 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 인돌 에테르 화합물 |
| EA202091484A1 (ru) | 2017-12-18 | 2021-03-25 | Бристол-Маерс Сквибб Компани | 4-азаиндольные соединения |
| SG11202005547YA (en) | 2017-12-19 | 2020-07-29 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| MX2020005462A (es) | 2017-12-19 | 2020-09-07 | Bristol Myers Squibb Co | Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr). |
| JP7304352B2 (ja) | 2017-12-19 | 2023-07-06 | ブリストル－マイヤーズ スクイブ カンパニー | ６－アザインドール化合物 |
| WO2019126081A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Amide substituted indole compounds useful as tlr inhibitors |
| EP3728218B1 (en) | 2017-12-20 | 2021-12-01 | Bristol-Myers Squibb Company | Amino indole compounds useful as tlr inhibitors |
| KR102730859B1 (ko) | 2017-12-20 | 2024-11-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 및 헤테로아릴 치환된 인돌 화합물 |
| SG11202005733QA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Diazaindole compounds |
| CN111432818A (zh) | 2017-12-22 | 2020-07-17 | 诺华股份有限公司 | 用于治疗神经精神性系统性红斑狼疮的吡唑并哌啶衍生物和吡唑并嘧啶衍生物 |
| JP7407740B2 (ja) | 2018-05-18 | 2024-01-04 | ノバルティス アーゲー | Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態 |
| AU2019282253A1 (en) | 2018-06-05 | 2020-11-26 | Altos Labs, Inc. | Inhibitors of integrated stress response pathway |
| TWI825144B (zh) | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | 第二型轉麩醯胺酸酶(tg2)抑制劑 |
| CN114728959B (zh) | 2019-11-12 | 2024-11-12 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡嗪并[1,2-b]异喹啉化合物 |
| US12503471B2 (en) | 2019-11-19 | 2025-12-23 | Hoffmann-La Roche Inc. | Triazatricycle compounds for the treatment of autoimmune disease |
| US20230041743A1 (en) | 2019-11-26 | 2023-02-09 | Hoffmann-La Roche Inc. | 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease |
-
2019
- 2019-06-03 EP EP19729220.4A patent/EP3802539B1/en active Active
- 2019-06-03 MX MX2020012827A patent/MX2020012827A/es unknown
- 2019-06-03 US US16/972,556 patent/US12157746B2/en active Active
- 2019-06-03 BR BR112020024782-0A patent/BR112020024782A2/pt not_active Application Discontinuation
- 2019-06-03 SG SG11202011137SA patent/SG11202011137SA/en unknown
- 2019-06-03 JP JP2020567772A patent/JP7374130B2/ja active Active
- 2019-06-03 CA CA3098291A patent/CA3098291A1/en active Pending
- 2019-06-03 MA MA052747A patent/MA52747A/fr unknown
- 2019-06-03 PE PE2020001875A patent/PE20210131A1/es unknown
- 2019-06-03 CR CR20200584A patent/CR20200584A/es unknown
- 2019-06-03 WO PCT/EP2019/064323 patent/WO2019233941A1/en not_active Ceased
- 2019-06-03 KR KR1020207034855A patent/KR20210018818A/ko not_active Ceased
- 2019-06-03 CN CN201980035182.7A patent/CN112204028B/zh active Active
- 2019-06-03 AU AU2019280728A patent/AU2019280728A1/en not_active Abandoned
- 2019-06-04 TW TW108119369A patent/TW202016111A/zh unknown
-
2020
- 2020-11-25 CL CL2020003065A patent/CL2020003065A1/es unknown
- 2020-11-26 CO CONC2020/0014677A patent/CO2020014677A2/es unknown
- 2020-12-01 IL IL279144A patent/IL279144A/en unknown
- 2020-12-04 PH PH12020552092A patent/PH12020552092A1/en unknown